| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/13/2005 | EP1434582B1 Topical composition containing brucine and the use for the treatment of damaged mammalian skin |
| 04/13/2005 | EP1367996A4 Sustained-release suspension of ceftiofur hydrochloride |
| 04/13/2005 | EP1353698A4 Recombinant serum albumin for use in cleansing or dermatological products for skin or hair |
| 04/13/2005 | EP1335706B1 Process fo r the production of microspheres of pancreatic enzymes with high stability |
| 04/13/2005 | EP1242576B1 Stabilizing diluent for polypeptides and antigens |
| 04/13/2005 | EP1214101A4 Method for detecting and killing epithelial cancer cells |
| 04/13/2005 | EP1196136B1 Compositions comprising organosiloxane resins for delivering oral care substances |
| 04/13/2005 | EP1115409A4 Composition for extending post meal satiety |
| 04/13/2005 | EP1113785B1 Clear aqueous solutions of bile acids |
| 04/13/2005 | EP0930893B1 Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| 04/13/2005 | CN1606620A Slow releasing protein polymer |
| 04/13/2005 | CN1606566A Integrin targeting compounds |
| 04/13/2005 | CN1606457A Methods for sterilizing preparations containing albumin |
| 04/13/2005 | CN1606455A Lyophilized preparation containing antibodies to the egf receptor |
| 04/13/2005 | CN1606454A Antibody targeting compounds |
| 04/13/2005 | CN1606452A Liquid composition of modified factor vii polypeptides |
| 04/13/2005 | CN1606450A Polypeptide, the conjugate thereof with doxorubicin and a pharmaceutical composition based thereon |
| 04/13/2005 | CN1606447A Storage-stable fibrinogen solutions |
| 04/13/2005 | CN1606446A Method for preventing and treating communicable diseases and other diseases using monosaccharides and disaccharides |
| 04/13/2005 | CN1606445A Process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2-enzyme inhibitors |
| 04/13/2005 | CN1606441A Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma |
| 04/13/2005 | CN1606438A 5HT4 partial agonist pharmaceutical compositions |
| 04/13/2005 | CN1606435A Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
| 04/13/2005 | CN1606432A Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| 04/13/2005 | CN1606430A Compositions and methods for high sorption of skin materials and delivery of sulfur |
| 04/13/2005 | CN1606406A Mitocidal compositions and methods |
| 04/13/2005 | CN1605359A Method for preparing embedded hydrophilic medicinal polymer minisphere or minisac carrier |
| 04/13/2005 | CN1196496C Dry acid-chitosan complexes |
| 04/13/2005 | CN1196489C Perfusion liquid preparations for ophthalmic operations |
| 04/13/2005 | CN1196486C Ziprasidone suspension liquid |
| 04/13/2005 | CN1196481C Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
| 04/13/2005 | CN1196476C Production method of oral cavitity quickly disintegrating tablets |
| 04/13/2005 | CN1196475C Bioavailable dosage form of isotretinoin |
| 04/13/2005 | CN1196474C Liposome-entrapped DNA oral vaccines |
| 04/12/2005 | US6878758 Polyhydroxyalkanoate compositions having controlled degradation rates |
| 04/12/2005 | US6878751 Administration of resveratrol to treat inflammatory respiratory disorders |
| 04/12/2005 | US6878747 Systemic formulations containing beta-carotene and derivatives thereof |
| 04/12/2005 | US6878548 Composition for use in electroporation |
| 04/12/2005 | US6878387 Core with an organic acid salt; acrylic blend coating of an interpolymer of a (meth)acrylate ester and a quaternary ammonium (meth)acrylate and a (meth)acrylate ester homo- or copolymer with an ester having acid or base groups |
| 04/12/2005 | US6878374 Made from divinyl ethers and diols that may be dimethylol terminated polyamines, polyamides or dendrimers; may be reacted with polynucleotides to form complexes for cell transfection |
| 04/12/2005 | US6878370 Chemically modified TNF-α |
| 04/12/2005 | CA2337745C Human growth hormone aqueous formulation |
| 04/12/2005 | CA2278106C Tissue factor methods and compositions for coagulation and tumor treatment |
| 04/12/2005 | CA2257172C Dissolvable oxides for biological applications |
| 04/12/2005 | CA2235041C Iodine complexes in powder form |
| 04/12/2005 | CA2142445C Injection solutions of azosemide which are ready for injection |
| 04/12/2005 | CA2131229C Bisconjugates comprising two saccharides and a spacer |
| 04/12/2005 | CA2123363C Lysosomal enzyme-cleavable antitumor drug conjugates |
| 04/12/2005 | CA2101742C Biodegradable polymer blends for drug delivery |
| 04/12/2005 | CA2086672C Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| 04/07/2005 | WO2005030266A2 Optical imaging of colorectal cancer |
| 04/07/2005 | WO2005030259A2 Nucleic acid-lipophilic conjugates |
| 04/07/2005 | WO2005030257A2 Water soluble nanoparticles inclusion complexes |
| 04/07/2005 | WO2005030253A2 Photocleavable dna transfer agent |
| 04/07/2005 | WO2005030248A1 Clostridium botulinum c3 exotransferase compositions and methods for treating tumour spreading |
| 04/07/2005 | WO2005030243A1 Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
| 04/07/2005 | WO2005030242A1 Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
| 04/07/2005 | WO2005030229A1 Probiotic storage and delivery |
| 04/07/2005 | WO2005030171A1 Delivery of therapeutic compounds via microparticles or microbubbles |
| 04/07/2005 | WO2005030170A2 Controlled rupture of furtive liposomes |
| 04/07/2005 | WO2005030168A1 Skin burn treatment ointment |
| 04/07/2005 | WO2005029980A1 Composition with relieved unpleasant odor or taste of cysteines |
| 04/07/2005 | WO2005010075A3 Method for preparing functionalized polymers from polymer alcohols |
| 04/07/2005 | WO2005009472A3 Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| 04/07/2005 | WO2004097017A3 Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
| 04/07/2005 | WO2004091538A3 Homogeneous, thermoreversible alginate films and soft capsules made therefrom |
| 04/07/2005 | WO2004091498A3 Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
| 04/07/2005 | WO2004070009A3 Targeted multivalent macromolecules |
| 04/07/2005 | US20050075498 Functionalized for wider applications; enhanced solvent solubility; simple reactions; ion sensors |
| 04/07/2005 | US20050075368 Solvent extracting natural E2,E4-decadienal and undecadienal from ground, dried fruit of piper species; oxidation, esterification and transamidation; taste and aroma enhancers; bactercidel, fungicide and insecticidide activity |
| 04/07/2005 | US20050075350 Adding a pyridonecarboxylic acid comprising lomefloxacin, norfloxacin, ofloxacin, enoxacin, ciprofloxacin, tosufloxacin, fleroxacin and/or levofloxacin; cinoxacin, sparfloxacin or salt; low temperature; antiinflammatory agents |
| 04/07/2005 | US20050075335 Pharmaceutical composition comprising n((1-n-butyl-4-piperidinyl)methyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indole-10-carboxamide or salt and process therefor comprising dry granulation |
| 04/07/2005 | US20050075319 Method of treatment using bisphosphonic acid |
| 04/07/2005 | US20050075313 Ophthalmic compositions containing galactomannan polymers and borate |
| 04/07/2005 | US20050075308 Methods and compositions for producing antigenic responses |
| 04/07/2005 | US20050075301 Pharmaceutical preparation with RNA as hemostasis cofactor |
| 04/07/2005 | US20050075296 for extending the release times and decreasing the toxicity, by using a di-lauric acid salt of tilmicosin in an acceptable solvent, which forms a precipitate when injected into water; treating infections in dogs and cats where tilmicosin was previously too toxic |
| 04/07/2005 | US20050075284 peptide analogues or conjugates of vasoactive intestinal peptide(VIP), used for vaginal relaxation and/or for modulation of sperm motility |
| 04/07/2005 | US20050075273 condensation aerosols; for treatment of pain or alcohol abuse; kits |
| 04/07/2005 | US20050075268 cell is contacted with a photosentistising agent, cell is irradiated with light to activate photosentisitising agent, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination |
| 04/07/2005 | US20050075102 Personal-call and feature control system and method for controlling telephones, providing extended features for such telephones and routing of media-rich calls |
| 04/07/2005 | US20050074884 Identification of peptides that facilitate uptake and cytoplasmic and /or nuclear transport of proteins, DNA and viruses |
| 04/07/2005 | US20050074866 Mixture comprising antihemophilic and/or von willebrand factors, antithrombin and sodium heparin for use as tool in treatment of blood disorders |
| 04/07/2005 | US20050074863 Chemoprotective agent comprising lymphocyte epitopes for use in treatment of cell proliferative disorders |
| 04/07/2005 | US20050074848 Major histocompatibility complex fusion comprising human cartilage oligomeric matrix protein (COMP) for use in prevention and treatment of cancer, infection, autoimmune and transplant rejection |
| 04/07/2005 | US20050074812 Molecules that home to various selected organs or tissues |
| 04/07/2005 | US20050074499 Specifically reacting with target such as tumor cell and tumor antigen existing inside |
| 04/07/2005 | US20050074498 Perforated microstructure; flowability, dispersibility; stable aerosols; respiratory inhalants |
| 04/07/2005 | US20050074497 Sustained release delivery systems; contact lens shape; includes vision correction; lower dosage antiangiogenesis therapeutics; reduced local inflammation and/or adverse systemic reactions; macular degeneration; retinopathies |
| 04/07/2005 | US20050074495 Compositions of polyacids and methods for their use in reducing adhesions |
| 04/07/2005 | US20050074492 Sustained release ionic conjugate |
| 04/07/2005 | US20050074491 Universal controlled-release composition |
| 04/07/2005 | US20050074490 Controlled release composition |
| 04/07/2005 | US20050074487 Transdermal and topical administration of drugs using basic permeation enhancers |
| 04/07/2005 | US20050074470 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 04/07/2005 | US20050074469 Storable and shippable concentrates; mixable with polymer formulations without heating, homogenizing or cooling |
| 04/07/2005 | US20050074462 Suppressing IgE immunoglobulin mediated hypersensitivity; transdermal administration |
| 04/07/2005 | US20050074461 Transdermal botulinum toxin compositions |
| 04/07/2005 | US20050074460 Reacting a protein with a hapten (especially a luteinizing hormone releasing hormone peptides derived from E coil, or malaria derived peptides) to produce a hapten-protein conjugate, followed by reacting the hapten-protein conjugate with a polysaccharide |
| 04/07/2005 | US20050074441 probiotics having immunomodulatory activity, used for prophylaxis gastrointestinal disorders such as inflammatory bowel disease or irritable bowel syndrome |